Ignite Creation Date:
2024-05-06 @ 4:22 PM
Last Modification Date:
2024-10-26 @ 2:09 PM
Study NCT ID:
NCT04963088
Status:
UNKNOWN
Last Update Posted:
2021-07-15
First Post:
2021-06-21
Brief Title:
TISLELIZUMAB Combined With Anlotinib and ChemotherapyXELOX in the Treatment of Advanced Gastric Carcinoma
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Organization Data
Organization:
The First Affiliated Hospital with Nanjing Medical University
Class:
OTHER
Study ID:
BGB-A317-ANLO-XELOX GC
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None